A randomized trial of conventional dose vs reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients

[Rinshō ketsueki] The Japanese journal of clinical hematology

Volumn 41, Issue 2, 2000, Pages 109-114

  Mori, M ^a   Nisimura, H ^a   Urabe, A ^a   Tamura, K ^a   Makino, S ^a   Okabe, K ^a   Tomiyama, J ^a   Hara, M ^a   Tanimoto, M ^a   Kikuchi, M ^a   Hamaguchi, H ^a   Sato, H ^a   Saburi, Y ^a  

^a Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BHAC DMPV PROTOCOL; BHAC-DMPV PROTOCOL; CYTARABINE; DAUNORUBICIN; DRUG DERIVATIVE; MERCAPTOPURINE; PREDNISOLONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION;

6-MERCAPTOPURINE; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; PREDNISOLONE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; VINCRISTINE;

EID: 0034132901     PISSN: 04851439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)